Evaluating the Patient at Cardiovascular Risk

Why This Matters

Preventing cardiovascular disease begins with identifying risk before symptoms develop. Although sophisticated biomarkers and advanced imaging continue to expand the understanding of cardiovascular disease, the foundation of risk assessment remains a careful clinical evaluation. The goal is not simply to identify elevated cholesterol, but to estimate a patient's lifetime exposure to atherogenic lipoproteins and determine whether intervention is warranted.

Begin with the Patient

Laboratory values should always be interpreted within the clinical context.

A thorough medical history often provides more useful information than a single laboratory measurement. Important considerations include age, sex, family history of premature atherosclerotic cardiovascular disease, smoking status, hypertension, diabetes mellitus, chronic kidney disease, obesity, physical activity, dietary habits, and previous cardiovascular events.

The physical examination may reveal clues such as tendon xanthomas, xanthelasma, corneal arcus in younger individuals, diminished peripheral pulses, carotid bruits, central obesity, or elevated blood pressure. Risk assessment begins with the patient, not the laboratory report.

The Standard Lipid Panel

The standard lipid panel remains the initial laboratory evaluation for most patients.

It includes total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. From these values, non-HDL cholesterol can be calculated without additional testing. For many individuals, this information is sufficient to guide treatment. However, the lipid panel measures cholesterol carried within lipoproteins rather than the number of circulating atherogenic particles.

ApoB

Whenever available, ApoB provides one of the most informative measurements in preventive cardiology.

Because every atherogenic lipoprotein contains one ApoB molecule, ApoB directly reflects the total number of circulating particles capable of entering and becoming retained within the arterial wall. ApoB is particularly valuable in patients with obesity, insulin resistance, metabolic syndrome, type 2 diabetes mellitus, or hypertriglyceridemia, where LDL cholesterol may underestimate cardiovascular risk.

Lipoprotein(a)

Lipoprotein(a) should be measured at least once during adulthood.

Because its concentration is determined predominantly by genetics and changes little over time, a single measurement is usually sufficient. Identifying elevated Lp(a) helps explain unexpected cardiovascular disease and identifies patients who may benefit from more intensive management of other modifiable risk factors.

Additional Biomarkers and Imaging

Selected patients may benefit from additional laboratory testing. High-sensitivity C-reactive protein (hs-CRP) provides information about systemic inflammation. LDL particle number, cholesterol absorption and synthesis markers, or other specialized lipid studies may further refine risk assessment in appropriate clinical settings.

Coronary artery calcium (CAC) scoring is particularly useful in selected asymptomatic individuals whose need for pharmacologic therapy remains uncertain. A higher CAC score reflects a greater burden of coronary atherosclerosis and often supports more aggressive risk reduction. In large cohort studies such as MESA, a CAC score of zero identifies a population in which a coronary event over the following several years is genuinely uncommon, which is why a zero score is sometimes used to defer pharmacologic therapy in lower-risk patients; how long that "warranty period" lasts before rescanning is reasonable depends on age, risk factors, and traditional risk score, and generally runs from about three to seven years rather than being fixed. Adding CAC data to traditional risk calculators measurably improves their ability to discriminate who will and won't have an event, which is a meaningfully different — and more clinically useful — claim than simply saying calcium scoring "helps." Carotid ultrasound and coronary CT angiography may also be appropriate in selected clinical situations.

Integrating the Information

No single laboratory value or imaging study should determine treatment in isolation.

The clinician must integrate clinical history, physical examination, lipid measurements, biomarkers, imaging findings, and patient preferences to develop an individualized prevention strategy. The ultimate objective is to reduce lifetime exposure to ApoB-containing lipoproteins while addressing all modifiable cardiovascular risk factors.

Clinical Pearls

• Cardiovascular risk assessment begins with a careful history and physical examination.
• The standard lipid panel remains the foundation of laboratory evaluation.
• ApoB provides the best estimate of atherogenic particle number.
• Lipoprotein(a) should generally be measured once during adulthood.
• Imaging studies complement, but do not replace, clinical judgment.

Common Misconceptions

Misconception: One abnormal laboratory value determines cardiovascular risk.

Reality: Risk assessment requires integrating clinical history, examination, laboratory data, imaging, and overall metabolic health.

Misconception: A normal LDL cholesterol excludes significant cardiovascular risk.

Reality: Elevated ApoB, Lp(a), remnant lipoproteins, or subclinical atherosclerosis may identify patients at increased risk despite acceptable LDL cholesterol levels.

Misconception: Advanced testing is necessary for every patient.

Reality: Most patients can be appropriately evaluated with a careful clinical assessment and a standard lipid panel. Additional testing should be reserved for situations in which it is likely to change management.

Clinical Bottom Line

Effective cardiovascular prevention begins with thoughtful risk assessment. The most valuable evaluation combines careful clinical judgment with appropriate laboratory testing and, when indicated, imaging.